Promising trial results of brigatinib show that all next-gen ALK inhibitors may not be created equal

Phase I/II clinical trial results show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. Progression-free survival (PFS) in patients previously treated with crizotinib was 13.4 months.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1cnuIgz